MedPath

VIDELA SEBASTIAN

🇦🇷Argentina
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:1

Trial Phases

2 Phases

Phase 2:1
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (50.0%)
Phase 2
1 (50.0%)

Effect and Safety of Listening to Music for Chronic Pain Relief

Not Applicable
Recruiting
Conditions
Chronic Pain
First Posted Date
2023-02-13
Last Posted Date
2023-07-06
Lead Sponsor
Sebastian Videla
Target Recruit Count
70
Registration Number
NCT05726266
Locations
🇪🇸

Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain

Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection

Phase 2
Completed
Conditions
COVID-19 Pneumonia
Interventions
Other: SoC
First Posted Date
2021-07-27
Last Posted Date
2022-08-03
Lead Sponsor
Sebastian Videla
Target Recruit Count
73
Registration Number
NCT04978051
Locations
🇪🇸

Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Catalonia, Spain

ANGIOTENSIN AGENTS AND REDUCTION OF THE PRESCRIPTION OF ANTIDEPRESSANT DRUGS: A RETROSPECTIVE COHORT STUDY USING REAL-WORLD DATA

Withdrawn
Conditions
Hypertension
ACE Inhibitors
ARB
Depression
Interventions
Drug: With an Antidepressant Drug
Drug: Without an Antidepressant Drug
First Posted Date
2021-05-24
Last Posted Date
2025-06-05
Lead Sponsor
Sebastian Videla
Target Recruit Count
120
Registration Number
NCT04899206
Locations
🇪🇸

Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Catalonia, Spain

News

No news found
© Copyright 2025. All Rights Reserved by MedPath